Naratuximab
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab) ) is a humanized monoclonal antibody that binds CD37 (TSPAN26) . Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine[1].
Product Specifications
CAS Number
1622327-39-2
Product Name Alternative
Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
UNSPSC
12352203
Target
ADC Antibody
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/naratuximab.html
Purity
99.9
Solubility
10 mM in DMSO
Smiles
[Naratuximab]
Molecular Weight
(143.6 kDa)
References & Citations
[1]Stuart W Hicks, et al. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia. 2017 Sep;19 (9) :661-671.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
